A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

作者：Cohen Stanley B^*; Alten Rieke; Kameda Hideto; Hala Tomas; Radominski Sebastiao C; Rehman Muhammad I; Palaparthy Ramesh; Schumacher Karl; Schmitt Susanne; Hua Steven Y; Ianos Claudia; Sewell K Lea

来源：Arthritis Research and Therapy, 2018, 20(1): 155.

DOI：10.1186/s13075-018-1646-4

• Infliximab
• PF-06438179/GP1111
• Biosimilar
• Rheumatoid arthritis
• Dose escalation

Background: This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly (R)), an infliximab biosimilar, vs infliximab (Remicade (R)) reference product sourced from the European Union (infliximab-EU) in biologic-naive patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate therapy. This paper reports results from the initial 30-week treatment period.
Methods: Patients (N = 650) were stratified by geographic region and randomized 1: 1 to PF-06438179/GP1111 or infliximab-EU (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks). Dose escalation to 5 mg/kg was allowed starting at week 14 for patients with inadequate RA response. The primary endpoint was American College of Rheumatology criteria for >= 20% clinical improvement (ACR20) response at week 14. Therapeutic equivalence was declared if the two-sided 95% CI for the treatment difference was within the symmetric equivalence margin of +/- 13.5%. Statistical analysis was also performed with a two-sided 90% CI using an asymmetric equivalence margin (-12.0%, 15.0%).
Results: Patients (80.3% female; 79.4% seropositive) had a mean RA duration of 6.9 years, and mean baseline Disease Activity Score in 28 joints, four components based on C-reactive protein was 6.0 in both arms. Week 14 ACR20 in the intention-to-treat population was 62.7% for PF-06438179/GP1111 and 64.1% for infliximab-EU. Week 14 ACR20 using nonresponder imputation was 61.1% for PF-06438179/GP1111 and 63.5% for infliximab-EU, and the 95% (-9.92%, 5.11%) and 90% (-8.75%, 4.02%) CIs for the treatment difference (-2.39%) were entirely contained within the prespecified symmetric and asymmetric equivalence margins, respectively. No differences were observed between arms for secondary efficacy endpoints. Overall postdose antidrug antibody (ADA) rates through week 30 were 48.6% and 51.2% for PF-06438179/GP1111 and infliximab-EU, respectively. Efficacy and immunogenicity were similar between treatments for patients with dose escalation (at or after week 14), as well as between treatments for patients without dose escalation. Safety profiles of PF-06438179/GP1111 and infliximab-EU were similar, with no clinically meaningful differences observed between arms, including after ADA development. Serum drug concentrations were similar between arms at each time point during the initial 30-week treatment period.
Conclusion: PF-06438179/GP1111 and infliximab-EU demonstrated similar efficacy, safety, immunogenicity, and PK with or without dose escalation in patients with moderate to severe active RA on background methotrexate.

• 出版日期2018-7-27